Mochida Pharmaceutical Co., Ltd. (TYO:4534)

Market Cap	110.43B +5.9%
Revenue (ttm)	116.95B +11.2%
Net Income	7.90B +39.0%
EPS	222.93 +39.0%
Shares Out	35.45M
PE Ratio	13.97
Forward PE	n/a
Dividend	85.00 (2.73%)
Ex-Dividend Date	Mar 30, 2026

Volume	54,200
Open	3,130.00
Previous Close	3,110.00
Day's Range	3,110.00 - 3,150.00
52-Week Range	2,910.00 - 3,965.00
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 3, 2026

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1913
• Employees: 1,479
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4534

Financial Performance

In fiscal year 2026, Mochida Pharmaceutical's revenue was 116.95 billion, an increase of 11.21% compared to the previous year's 105.16 billion. Earnings were 7.90 billion, an increase of 39.01%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 14, 2026

Data Sources Report a data error